- Home
- APLT vs CKPT Comparison
APLT vs CKPT Comparison
Compare APLT & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- CKPT
- Stock Information
- Founded
- APLT 2016
- CKPT 2014
- Country
- APLT United States
- CKPT United States
- Employees
- APLT N/A
- CKPT N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- CKPT Health Care
- Exchange
- APLT Nasdaq
- CKPT Nasdaq
- Market Cap
- APLT 128.0M
- CKPT 151.9M
- IPO Year
- APLT 2019
- CKPT 2017
- Fundamental
- Price
- APLT $0.65
- CKPT $3.18
- Analyst Decision
- APLT Buy
- CKPT Strong Buy
- Analyst Count
- APLT 7
- CKPT 2
- Target Price
- APLT $6.10
- CKPT $13.50
- AVG Volume (30 Days)
- APLT 7.5M
- CKPT 1.3M
- Earning Date
- APLT 03-05-2025
- CKPT 11-12-2024
- Dividend Yield
- APLT N/A
- CKPT N/A
- EPS Growth
- APLT N/A
- CKPT N/A
- EPS
- APLT N/A
- CKPT N/A
- Revenue
- APLT N/A
- CKPT $47,000.00
- Revenue This Year
- APLT N/A
- CKPT N/A
- Revenue Next Year
- APLT $2,622.90
- CKPT $172,016.02
- P/E Ratio
- APLT N/A
- CKPT N/A
- Revenue Growth
- APLT N/A
- CKPT N/A
- 52 Week Low
- APLT $0.60
- CKPT $1.38
- 52 Week High
- APLT $10.62
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- APLT 20.60
- CKPT 42.32
- Support Level
- APLT $0.60
- CKPT $3.07
- Resistance Level
- APLT $0.74
- CKPT $3.42
- Average True Range (ATR)
- APLT 0.09
- CKPT 0.21
- MACD
- APLT 0.21
- CKPT -0.02
- Stochastic Oscillator
- APLT 13.53
- CKPT 15.71
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.